Panther Biotechnology Announces New Chief Executive Officer

CHICAGO, IL--(Marketwired - March 23, 2015) - Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that Evan Levine has accepted the position of Chief Executive Officer, as well as a seat on the Board of Directors.

Panther Biotechnology, Inc. is an entity focused on the acquisition of unique molecules and the development of therapeutics for the treatment of several types of cancer and autoimmune disorders. A key component of the business plan has been to hire a CEO focused on company growth. The Panther Biotechnology Board of Directors has spent a great deal of time searching for the right person to lead the Company. "Mr. Levine's background in executive management, finance and biotechnology brings us into an exciting time for Panther Biotechnology," said Izzy Zalcberg, Chairman of the Board. "We look forward to a phase of strong growth and development as we expand into multiple areas of oncology and autoimmune disorders as well."

"I am looking forward to growing the intellectual property portfolio and moving exciting new therapeutic compounds through the clinic towards New Drug Applications," stated Mr. Levine. "It is exciting to be leading a new business that already has such strong relationships within the field. I look forward to continuing to cultivate these alliances, build new associations, and assemble a world class team of both business and science professionals."

Mr. Levine brings over two decades plus of in-depth experience in executive management and the institutional investment business with expertise that includes initiating, restructuring, and managing corporate infrastructure with knowledge and skill to increase investor and shareholder net worth. Mr. Levine has executed and orchestrated corporate restructurings and change management dealings that resulted in the successful turnaround of several publicly traded companies. Mr. Levine acquired and reorganized the struggling biotech company, Adventrx Pharmaceuticals, with investment partners and architected the restructuring of the management, board of directors and the strategic development programs. This resulted in turning a pre-money valuation of less than $700,000 to a market capitalization high of over $550 million. Mr. Levine initiated the Brown Simpson Strategic Growth Fund with three investment partners and initial capital of $400,000 which increased to more than $650 million within three years.

Richard Rainey, the former Chief Executive Officer and Chief Financial Officer, is no longer with the Company.

David Moss has resigned from the Board of Directors.

Panther Biotechnology, Inc. is an entity focused on the acquisition and development of therapeutics for the treatment of several types of cancer and autoimmune disorders. The company will focus on identifying promising anti-cancer therapeutic candidates that are optimized derivatives of widely studied products or re-purposed existing marketed compounds. 


Panther Biotechnology, Inc.
Evan Levine
Chief Executive Officer
(650) 305-0553

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.